2007 JASN IMPACT FACTOR 7.111	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) All Versions of this Article: ASN.2004080686v1 16/4/1076    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chan, T.-M. Search for Related Content PubMed PubMed Citation Articles by Chan, T.-M.

Long-Term Study of Mycophenolate Mofetil as Continuous Induction and Maintenance Treatment for Diffuse Proliferative Lupus Nephritis

Department of Medicine, University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong

Address correspondence to: Prof. Tak-Mao Chan, Department of Medicine, University of Hong Kong, Queen Mary Hospital, New Clinical Building, Room 303, Pokfulam Road, Hong Kong. Phone: 852-2855-4542; Fax: 852-2872-5828; dtmchan{at}hkucc.hku.hk

Received for publication August 19, 2004. Accepted for publication January 16, 2005.

Mycophenolate mofetil (MMF) and the sequential use of cyclophosphamide followed by azathioprine (CTX-AZA) demonstrate similar short-term efficacy in the treatment of diffuse proliferative lupus nephritis (DPLN), but MMF is associated with less drug toxicity. Results from an extended long-term study, with median follow-up of 63 mo, that investigated the role of MMF as continuous induction-maintenance treatment for DPLN are presented. Thirty-three patients were randomized to receive MMF, and 31 were randomized to the CTX-AZA treatment arm, both in combination with prednisolone. More than 90% in each group responded favorably (complete or partial remission) to induction treatment. Serum creatinine in both groups remained stable and comparable over time. Creatinine clearance increased significantly in the MMF group, but the between-group difference was insignificant. Improvements in serology and proteinuria were comparable between the two groups. A total of 6.3% in the MMF group and 10.0% of CTX-AZA–treated patients showed doubling of baseline creatinine during follow-up (P = 0.667). Both the relapse-free survival and the hazard ratio for relapse were similar between MMF- and CTX-AZA–treated patients (11 and nine patients relapsed, respectively) and between those with MMF treatment for 12 or 24 mo. MMF treatment was associated with fewer infections and infections that required hospitalization (P = 0.013 and 0.014, respectively). Four patients in the CTX-AZA group but none in the MMF group reached the composite end point of end-stage renal failure or death (P = 0.062 by survival analysis). It is concluded that MMF and prednisolone constitute an effective continuous induction-maintenance treatment for DPLN in Chinese patients.

This article has been cited by other articles:

				K. C. TSE, C. S.O. TANG, M. F. LAM, D. Y.H. YAP, and T. M. CHAN Cost Comparison Between Mycophenolate Mofetil and Cyclophosphamide-Azathioprine in the Treatment of Lupus Nephritis J Rheumatol, January 1, 2009; 36(1): 76 - 81. [Abstract] [Full Text] [PDF]

				J. Lv, H. Zhang, Z. Cui, T. Su, Y. Zhang, and H. Wang Delayed severe pneumonia in mycophenolate mofetil-treated patients with IgA nephropathy Nephrol. Dial. Transplant., September 1, 2008; 23(9): 2868 - 2872. [Abstract] [Full Text] [PDF]

				O Traitanon, Y Avihingsanon, V Kittikovit, N Townamchai, T Kanjanabuch, K Praditpornsilpa, J Wongchinasri, K Tungsanga, and S Eiam-Ong Efficacy of enteric-coated mycophenolate sodium in patients with resistant-type lupus nephritis: a prospective study Lupus, August 1, 2008; 17(8): 744 - 751. [Abstract] [PDF]

				T. Chan Mycophenolate mofetil in the treatment of lupus nephritis - 7 years on Lupus, July 1, 2008; 17(7): 617 - 621. [PDF]

				L. F, T. Y, P. X, W. L, W. H, S. Z, Z. H, and H. Z A prospective multicentre study of mycophenolate mofetil combined with prednisolone as induction therapy in 213 patients with active lupus nephritis Lupus, July 1, 2008; 17(7): 622 - 629. [Abstract] [PDF]

				F. Houssiau and E. Ginzler Current treatment of lupus nephritis Lupus, May 1, 2008; 17(5): 426 - 430. [Abstract] [PDF]

				W. F. Clark and J. M. Sontrop What Have We Learned about Optimal Induction Therapy for Lupus Nephritis (III through V) from Randomized, Controlled Trials? Clin. J. Am. Soc. Nephrol., May 1, 2008; 3(3): 895 - 898. [Full Text] [PDF]

				S. Lui, S Yung, R Tsang, F Zhang, K. Chan, S Tam, and T. Chan Rapamycin prevents the development of nephritis in lupus-prone NZB/W F1 mice Lupus, April 1, 2008; 17(4): 305 - 313. [Abstract] [PDF]

				G Bertsias, J P A Ioannidis, J Boletis, S Bombardieri, R Cervera, C Dostal, J Font, I M Gilboe, F Houssiau, T Huizinga, et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics Ann Rheum Dis, February 1, 2008; 67(2): 195 - 205. [Abstract] [Full Text] [PDF]

				Y. E. Chen, S. M. Korbet, R. S. Katz, M. M. Schwartz, E. J. Lewis, and for the Collaborative Study Group Value of a Complete or Partial Remission in Severe Lupus Nephritis Clin. J. Am. Soc. Nephrol., January 1, 2008; 3(1): 46 - 53. [Abstract] [Full Text] [PDF]

				A. Sinclair, G. Appel, M.A. Dooley, E. Ginzler, D. Isenberg, D. Jayne, D. Wofsy, and N. Solomons Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS) Lupus, December 1, 2007; 16(12): 972 - 980. [Abstract] [PDF]

				W.P. de Castro, J.V. Morales, M.B. Wagner, M. Graudenz, M.I. Edelweiss, and L.F. Goncalves Hypertension and Afro-descendant ethnicity: a bad interaction for lupus nephritis treated with cyclophosphamide? Lupus, September 1, 2007; 16(9): 724 - 730. [Abstract] [PDF]

				M. Walsh, M. James, D. Jayne, M. Tonelli, B. J. Manns, and B. R. Hemmelgarn Mycophenolate Mofetil for Induction Therapy of Lupus Nephritis: A Systematic Review and Meta-Analysis Clin. J. Am. Soc. Nephrol., September 1, 2007; 2(5): 968 - 975. [Abstract] [Full Text] [PDF]

				G. Contreras and J. Sosnov Role of Mycophenolate Mofetil in the Treatment of Lupus Nephritis Clin. J. Am. Soc. Nephrol., September 1, 2007; 2(5): 879 - 882. [Full Text] [PDF]

				B. Zhu, N. Chen, Y. Lin, H. Ren, W. Zhang, W. Wang, X. Pan, and H. Yu Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials Nephrol. Dial. Transplant., July 1, 2007; 22(7): 1933 - 1942. [Abstract] [Full Text] [PDF]

				P. M Stassen, J. W. Cohen Tervaert, and C. A Stegeman Induction of remission in active anti-neutrophil cytoplasmic antibody-associated vasculitis with mycophenolate mofetil in patients who cannot be treated with cyclophosphamide Ann Rheum Dis, June 1, 2007; 66(6): 798 - 802. [Abstract] [Full Text] [PDF]

				P. M. Stassen, C. G. M. Kallenberg, and C. A. Stegeman Use of mycophenolic acid in non-transplant renal diseases Nephrol. Dial. Transplant., April 1, 2007; 22(4): 1013 - 1019. [Full Text] [PDF]

				F Houssiau Thirty years of cyclophosphamide: assessing the evidence Lupus, March 1, 2007; 16(3): 212 - 216. [Abstract] [PDF]

				D Jayne Current management of lupus nephritis: popular misconceptions Lupus, March 1, 2007; 16(3): 217 - 220. [Abstract] [PDF]

				M Haubitz Exploring new territory: the move towards individualised treatment Lupus, March 1, 2007; 16(3): 227 - 231. [Abstract] [PDF]

				S. I. Nihtyanova, G. M. Brough, C. M. Black, and C. P. Denton Mycophenolate mofetil in diffuse cutaneous systemic sclerosis--a retrospective analysis Rheumatology, March 1, 2007; 46(3): 442 - 445. [Abstract] [Full Text] [PDF]

				K C Tse, M F Lam, S C. Tang, C S. Tang, and T M Chan A pilot study on tacrolimus treatment in membranous or quiescent lupus nephritis with proteinuria resistant to angiotensin inhibition or blockade Lupus, January 1, 2007; 16(1): 46 - 51. [Abstract] [PDF]

				A Doria, L Iaccarino, S Arienti, M E Rampudda, M G Canova, R Rondinone, and S Todesco Mycophenolate mofetil and systemic lupus erythematosus Lupus, November 1, 2006; 15(11_suppl): 44 - 54. [Abstract] [PDF]

				D. C. Preddie, G. S. Markowitz, J. Radhakrishnan, T. L. Nickolas, V. D. D'Agati, J. A. Schwimmer, M. Gardenswartz, R. Rosen, and G. B. Appel Mycophenolate Mofetil for the Treatment of Interstitial Nephritis Clin. J. Am. Soc. Nephrol., July 1, 2006; 1(4): 718 - 722. [Abstract] [Full Text] [PDF]

				C. Ponticelli New Therapies for Lupus Nephritis Clin. J. Am. Soc. Nephrol., July 1, 2006; 1(4): 863 - 868. [Full Text] [PDF]

				C C Mok, A Mak, and C H To Mycophenolate mofetil for lupus related myelopathy. Ann Rheum Dis, July 1, 2006; 65(7): 971 - 973. [Full Text] [PDF]

				K C Tse, C S. Tang, W I Lio, M F Lam, and T M Chan Quality of life comparison between corticosteroidand-mycofenolate mofetil and corticosteroidand-oral cyclophosphamide in the treatment of severe lupus nephritis Lupus, June 1, 2006; 15(6): 371 - 379. [Abstract] [PDF]

				M A Dooley Mycophenylate mofetil: what role in the treatment of lupus? Lupus, March 1, 2006; 15(3): 179 - 182. [Abstract] [PDF]

				K C Tse, F K Li, S Tang, C S-O Tang, K N Lai, and T M Chan Angiotensin inhibition or blockade for the treatment of patients with quiescent lupus nephritis and persistent proteinuria Lupus, December 1, 2005; 14(12): 947 - 952. [Abstract] [PDF]

				M. S. Joy, S. L. Hogan, J. C. Jennette, R. J. Falk, and P. H. Nachman A pilot study using mycophenolate mofetil in relapsing or resistant ANCA small vessel vasculitis Nephrol. Dial. Transplant., December 1, 2005; 20(12): 2725 - 2732. [Abstract] [Full Text] [PDF]

				E. M. Ginzler, M. A. Dooley, C. Aranow, M. Y. Kim, J. Buyon, J. T. Merrill, M. Petri, G. S. Gilkeson, D. J. Wallace, M. H. Weisman, et al. Mycophenolate Mofetil or Intravenous Cyclophosphamide for Lupus Nephritis. N. Engl. J. Med., November 24, 2005; 353(21): 2219 - 2228. [Abstract] [Full Text] [PDF]

				W. J. McCune Mycophenolate Mofetil for Lupus Nephritis. N. Engl. J. Med., November 24, 2005; 353(21): 2282 - 2284. [Full Text] [PDF]

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673